Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide or Tirzepatide, for the Treatment of Obesity

X
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide or Tirzepatide, for the Treatment of Obesity

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RDX-002 (Primary)
  • Indications Weight gain
  • Focus Pharmacokinetics
  • Sponsors Response Pharmaceuticals
  • Most Recent Events

    • 18 Oct 2024 According to a Response Pharmaceuticals, Inc media release, data from this study are expected in the second half of 2025.
    • 18 Oct 2024 According to a Response Pharmaceuticals, Inc media release, company today announced initiation of enrollment (Enrollment of First Patients) in a Phase 2 trial evaluating RDX-002, for post-GLP-1 weight rebound.
    • 17 Oct 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top